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n.Transcatheter heart valve (THV) implantation
with the valve-in-valve technique is a low-risk
treatment option for patients with failing biopros-
thetic valves (1).
A 71-year-old man with rheumatic mitral ste-
nosis underwent mitral valve replacement 12 years
ago with a 27-mm Carpentier-Edwards biopros-
thesis (Edwards Lifesciences, Inc., Irvine, Califor-
nia). He presented with biventricular failure due to
severe prosthetic mitral stenosis (valve area 0.8
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valvuloplasty. Surgical risk was deemed unaccept-
ably high (Logistic EuroScore  44.8%; Society of
Thoracic Surgeons predicted risk of mortality 
5.3%). Thus, he underwent transcatheter mitral
valve-in-valve implantation by the transvenous-
transeptal-anterograde approach, performed under
local anesthesia and conscious sedation. After
transseptal puncture, a Swan-Ganz catheter was
manipulated across the mitral prosthesis and aortic
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1247valve into the ascending aorta. A 260-cm, 0.035-inch
Amplatz Extra Stiff guidewire (Cook, Inc., Bloomington,
Indiana) was advanced into the descending aorta and snared
with a 25-mm gooseneck, creating a venous–arterial circuit
(Fig. 1A). The gooseneck was left attached to the Amplatz
wire to allow sufficient length of the wire system (Fig. 1B).
A 24-F Edwards sheath was placed in the right femoral
vein, and the atrial septum was dilated with a 10  40 mm
balloon. A 26-mm Sapien XT valve (Edwards Lifesciences)
premounted on the Novaflex system could not cross the
septum; the THV was retrieved, and further sepal dilation
with a larger balloon was performed (Fig. 1C). The THV
was re-advanced, and despite several attempts, coaxial po-
sitioning within the bioprosthesis was impossible (Fig. 2A).
During rapid ventricular pacing to minimize movement,
slow and gradual balloon inflation resulted in the valve
Figure 2. THV Positioning and Implantation
(A) Angiographic view perpendicular to the mitral bioprosthesis (55° right ant
middle of the Sapien XT (Edwards Lifesciences, Inc., Irvine, California) positione
rapid ventricular pacing with the Sapien XT (Edwards Lifesciences) moving spo
the Carpentier-Edwards bioprosthesis (Edwards Lifesciences). Note how the Sabecoming coaxial with an excellent final position (Figs. 2Band 2C). Transesophageal echocardiography demonstrated
a well-functioning Sapien XT valve (Edwards Lifesciences),
minimal mitral gradient (3 mm Hg), and moderate inter-
valvular mitral regurgitation (i.e., between the bioprosthesis
and Sapien XT). The patient tolerated the procedure well
and was discharged 5 days later with marked symptomatic
improvement. At 1-month follow-up, he was asymptomatic
with no mitral regurgitation.
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